Shares of BIOLINERX LTD/S (NASDAQ:BLRX) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $3.00.
BLRX has been the topic of several research reports. HC Wainwright set a $4.00 price objective on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Monday, October 22nd. Zacks Investment Research raised shares of BIOLINERX LTD/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 7th. Maxim Group reissued a “buy” rating and set a $2.00 price objective on shares of BIOLINERX LTD/S in a research report on Thursday, November 8th. Finally, Oppenheimer set a $3.00 price objective on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Friday, November 9th.
Several hedge funds have recently added to or reduced their stakes in the company. Two Sigma Securities LLC acquired a new stake in shares of BIOLINERX LTD/S in the 4th quarter worth $25,000. Menta Capital LLC acquired a new stake in shares of BIOLINERX LTD/S in the 4th quarter worth $33,000. ETF Managers Group LLC lifted its stake in shares of BIOLINERX LTD/S by 79.4% in the 4th quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 166,386 shares during the period. Finally, Fosun International Ltd acquired a new stake in shares of BIOLINERX LTD/S in the 3rd quarter worth $1,412,000. Institutional investors own 36.11% of the company’s stock.
BIOLINERX LTD/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Featured Article: What is a Derivative?
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.